GENLISA™ Human Anti-SARS-CoV-2 (Covid-19) IgG to nucleoprotein Omicron Variant (B.1.1.529)+Delta (B.1.617.2) Quantitative TITRATION ELISA

ELISA for quantitative estimation of Anti-SARS-CoV-2 IgG antibodies to nucleocasid (N) protein of the Omicron Variant (B.1.1.529) +Delta variant (B.1.617.2) in human serum and plasma samples. Lead time iseeks. IFUatasheet coming soon

Introduction:
The GENLISA™ ELISA kits are used for assessing the specific biomarker in samples analytes which may be
serum, plasma and cell culture supernatant as validated with the kit. The kit employs a sandwich ELISA
technique which leads to a higher specificity and increased sensitivity compared to conventional competitive
ELISA kits which employ only one antibody.

Intended Use:
The GENLISA™ Human Anti-SARS-CoV-2 (Covid-19) IgG to nucleoprotein Omicron Variant (B.1.1.529)+Delta
(B.1.617.2) Quantitative TITRATION ELISA kit is used as an analytical tool for quantitative estimation of AntiSARS-CoV-2 (2019-nCoV) nucleoprotein Omicron Variant (B.1.1.529)+Delta (B.1.617.2) antibodies in Human
serum.

Principle:
The method employs indirect sandwich ELISA technique. SARS-CoV-2 nucleoprotein Omicron Variant
(B.1.1.529)+Delta (B.1.617.2) is pre-coated onto microwells. Samples and standards are pipetted into
microwells and Antibodies to Human SARS-CoV-2 (2019-nCoV) nucleoprotein Omicron Variant
(B.1.1.529)+Delta (B.1.617.2) present in the sample are bound by the protein antigen. After incubation the
wells are washed and followed by addition of HRP-conjugated Detection IgG Antibody into each well and
incubated to form a complex. After washing microwells in order to remove any non-specific binding, the
substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Human
Anti-SARS-CoV-2 (2019-nCoV) nucleoprotein Omicron Variant (B.1.1.529)+Delta (B.1.617.2) antibodies in the
sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.